Search: onr:"swepub:oai:DiVA.org:uu-394059" > Treatment Outcomes ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07798naa a2200997 4500 | |
001 | oai:DiVA.org:uu-394059 | |
003 | SwePub | |
008 | 191002s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3940592 URI |
024 | 7 | a https://doi.org/10.1093/cid/ciy9882 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Dickstein, Yaakovu Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel4 aut |
245 | 1 0 | a Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections :b An Exploratory Subgroup Analysis of a Randomized Clinical Trial |
264 | c 2018-11-20 | |
264 | 1 | b OXFORD UNIV PRESS INC,c 2019 |
338 | a print2 rdacarrier | |
520 | a Background We evaluated the association between mortality and colistin resistance in Acinetobacter baumannii infections and the interaction with antibiotic therapy. Methods This is a secondary analysis of a randomized controlled trial of patients with carbapenem-resistant gram-negative bacterial infections treated with colistin or colistin-meropenem combination. We evaluated patients with infection caused by carbapenem-resistant A. baumannii (CRAB) identified as colistin susceptible (CoS) at the time of treatment and compared patients in which the isolate was confirmed as CoS with those whose isolates were retrospectively identified as colistin resistant (CoR) when tested by broth microdilution (BMD). The primary outcome was 28-day mortality. Results Data were available for 266 patients (214 CoS and 52 CoR isolates). Patients with CoR isolates had higher baseline functional capacity and lower rates of mechanical ventilation than patients with CoS isolates. All-cause 28-day mortality was 42.3% (22/52) among patients with CoR strains and 52.8% (113/214) among patients with CoS isolates (P = .174). After adjusting for variables associated with mortality, the mortality rate was lower among patients with CoR isolates (odds ratio [OR], 0.285 [95% confidence interval {CI}, .118-.686]). This difference was associated with treatment arm: Mortality rates among patients with CoR isolates were higher in those randomized to colistin-meropenem combination therapy compared to colistin monotherapy (OR, 3.065 [95% CI, 1.021-9.202]). Conclusions Colistin resistance determined by BMD was associated with lower mortality among patients with severe CRAB infections. Among patients with CoR isolates, colistin monotherapy was associated with a better outcome compared to colistin-meropenem combination therapy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
653 | a Acinetobacter | |
653 | a carbapenem-resistant | |
653 | a colistin | |
653 | a gram-negative bacteria | |
653 | a XDR-TB | |
700 | 1 | a Lellouche, Jonathanu Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel4 aut |
700 | 1 | a Amar, Maayan Ben Dalaku Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel4 aut |
700 | 1 | a Schwartz, Davidu Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel4 aut |
700 | 1 | a Nutman, Amiru Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel4 aut |
700 | 1 | a Daitch, Veredu Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel;Beilinson Med Ctr, Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel4 aut |
700 | 1 | a Yahav, Dafnau Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel;Beilinson Med Ctr, Rabin Med Ctr, Unit Infect Dis, Petah Tiqwa, Israel4 aut |
700 | 1 | a Leibovici, Leonardu Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel;Beilinson Med Ctr, Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel4 aut |
700 | 1 | a Skiada, Annau Laikon Gen Hosp, Dept Med 1, Athens, Greece;Univ Athens, Athens, Greece4 aut |
700 | 1 | a Antoniadou, Anastasiau Univ Athens, Athens, Greece;Attikon Univ Gen Hosp, Dept Med 4, Athens, Greece4 aut |
700 | 1 | a Daikos, George L.u Laikon Gen Hosp, Dept Med 1, Athens, Greece;Univ Athens, Athens, Greece4 aut |
700 | 1 | a Andini, Robertou Univ Campania L Vanvitelli, Dept Precis Med, Naples, Italy;Azienda Osped Rilievo Nazl Colli Monaldi Hosp, Naples, Italy4 aut |
700 | 1 | a Zampino, Rosau Univ Campania L Vanvitelli, Dept Precis Med, Naples, Italy;Azienda Osped Rilievo Nazl Colli Monaldi Hosp, Naples, Italy4 aut |
700 | 1 | a Durante-Mangoni, Emanueleu Univ Campania L Vanvitelli, Dept Precis Med, Naples, Italy;Azienda Osped Rilievo Nazl Colli Monaldi Hosp, Naples, Italy4 aut |
700 | 1 | a Mouton, Johan W.u Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands4 aut |
700 | 1 | a Friberg, Lenau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)lenasimo |
700 | 1 | a Benattar, Yael Dishonu Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel;Univ Haifa, Cheryl Spencer Dept Nursing, Haifa, Israel4 aut |
700 | 1 | a Bitterman, Roniu Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel4 aut |
700 | 1 | a Neuberger, Amiu Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel4 aut |
700 | 1 | a Carmeli, Yehudau Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel;Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel4 aut |
700 | 1 | a Paul, Micalu Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel;Technion Israel Inst Technol, Fac Med, Haifa, Israel4 aut |
700 | 1 | a Zayyad, Hiba4 aut |
700 | 1 | a Koppel, Fidi4 aut |
700 | 1 | a Zak-Doron, Yael4 aut |
700 | 1 | a Altunin, Sergey4 aut |
700 | 1 | a Andria, Nizar4 aut |
700 | 1 | a Stern, Anat4 aut |
700 | 1 | a Petersiel, Neta4 aut |
700 | 1 | a Raines, Marina4 aut |
700 | 1 | a Karban, Amir4 aut |
700 | 1 | a Eliakim-Raz, Noa4 aut |
700 | 1 | a Zusman, Oren4 aut |
700 | 1 | a Elbaz, Michal4 aut |
700 | 1 | a Atamna, Heyam4 aut |
700 | 1 | a Babich, Tanya4 aut |
700 | 1 | a Adler, Amos4 aut |
700 | 1 | a Levi, Inbar4 aut |
700 | 1 | a Pavleas, Ioannis4 aut |
700 | 1 | a Kotsaki, Antigoni4 aut |
700 | 1 | a Iossa, Domenico4 aut |
700 | 1 | a Bernardo, Mariano4 aut |
700 | 1 | a Cavezza, Giusi4 aut |
700 | 1 | a Bertolino, Lorenzo4 aut |
700 | 1 | a Giuffre, Giuseppe4 aut |
700 | 1 | a Giurazza, Roberto4 aut |
700 | 1 | a Cuccurullo, Susanna4 aut |
700 | 1 | a Galdo, Maria4 aut |
700 | 1 | a Murino, Patrizia4 aut |
700 | 1 | a Cristinziano, Adriano4 aut |
700 | 1 | a Corcione, Antonio4 aut |
700 | 1 | a Pafundi, Pia Clara4 aut |
700 | 1 | a Mouton, Johan4 aut |
700 | 1 | a Friberg, Lena4 aut |
700 | 1 | a Kristoffersson, Anders4 aut |
700 | 1 | a Theuretzbacher, Ursula4 aut |
710 | 2 | a Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israelb Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel4 org |
773 | 0 | t Clinical Infectious Diseasesd : OXFORD UNIV PRESS INCg 69:5, s. 769-776q 69:5<769-776x 1058-4838x 1537-6591 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-394059 |
856 | 4 8 | u https://doi.org/10.1093/cid/ciy988 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view